Pay in 4 interest-free payments of $50.00 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Studies have found that 66%-80% of NUT carcinomas harbor a BRD4-NUTM1 fusion gene while the remaining NUT carcinomas involve the BRD3-NUTM1
CD5 serves to mitigate activating signals from the BCR so that the B-1 cells can only be activated by very strong stimuli (such as bacterial proteins) and not by normal tissue proteins
in accordance with the general steps to make frozen section and paraffin section
Different with so many other heart markers
CD25/IL-2Rα, FOXP3, CD4 Antibody Panel Size:100μl Studies have found that 66%-80%Product Specification Antibody Type Recombinant mAb Application mIHC Reactivity Hu Conjugation Unconjugated Physical Appearance Liquid Storage Buffer PBS, 40% Glycerol, 0. 05% BSA, 0. 03% Proclin 300 Stability & Storage 12 months from date of receipt reconstitution, 20 C as supplied Dilution application dilution species mIHC 1: 200 Background CD25 IL 2R, FOXP3, CD4 Antibody Panel contains 3 recombinant monoclonal antibodies against CD25 IL 2R, FOXP3,
US$ 1132.50
US$ 38.44
US$ 89.00
US$ 115.00
US$ 287.50
US$ 747.50
US$ 612.50
US$ 125.00
US$ 650.98
US$ 706.98
US$ 850.48
US$ 670.98
US$ 125.00
US$ 27251.50
US$ 24.50